ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Swain Discusses the Final OS Analysis from the CLEOPATRA Study

Sandra M. Swain, MD
Published: Sunday, Sep 28, 2014

Sandra M. Swain, MD, Medical Director of the Washington Cancer Institute at MedStar Washington Hospital Center, discusses final overall survival (OS) analysis from the CLEOPATRA study of first-line pertuzumab, trastuzumab, and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer.

Median OS was 40.8 months in the placebo arm and 56.5 months in the pertuzumab arm — a different of 15.7 months. This is truly a remarkable improvement, Swain says.

Monoclonal antibodies have changed the trajectory of the disease in many patients with HER2-positive metastatic breast cancer, Swain says, and they are now able to live fairly normal lives.

<<< View more from the 2014 ESMO Congress

Sandra M. Swain, MD, Medical Director of the Washington Cancer Institute at MedStar Washington Hospital Center, discusses final overall survival (OS) analysis from the CLEOPATRA study of first-line pertuzumab, trastuzumab, and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer.

Median OS was 40.8 months in the placebo arm and 56.5 months in the pertuzumab arm — a different of 15.7 months. This is truly a remarkable improvement, Swain says.

Monoclonal antibodies have changed the trajectory of the disease in many patients with HER2-positive metastatic breast cancer, Swain says, and they are now able to live fairly normal lives.

<<< View more from the 2014 ESMO Congress


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x